TriplePoint Venture Growth BDC Corp.

Stage 2 · Advancing · week 3

As of Oct 22, 2026, TriplePoint Venture Growth BDC is in Stage 2, the uptrend phase, now in week 3 (since Oct 7, 2026). It closed at $4.30, 25.9% below its 52-week high and below its 200-day average, which is falling.

TriplePoint Venture Growth BDC Corp. is a business development company specializing investments in venture capital-backed companies at the growth stage investments. More about the company

$4.30

+1.18% today

$175M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 45 in Asset Management · #1 of 215 in Financials

Is TPVG early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 3w → S3 4w → S4 10w → S1 4w → S2 9w → S3 3w → S4 10w → S1 2w → S4 21w → S1 8w → S2 11w → S3 3w → S4 8w → S1 4w → S2 5w → S3 4w → S4 12w → S1 3w → S2 7w → S3 2w → S4 10w → S1 8w → S4 8w → S1 5w → S2 2w current

Total tracked: 165 weeks across 25 stage runs.

TPVG among Asset Management63rd of 140 by relative strength

All 140 →

Stocks in Asset Management ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CYPHCypherpunk Technologies Inc.	Stage 2 · wk 7	99	−17.5%
2	AMTDAMTD IDEA Group Class A	Stage 2 · wk 1	99	+4011.1%
3	MGLDThe Marygold Companies, Inc.	Stage 2 · wk 4	94	+105.2%
4	AAMIAcadian Asset Management Inc.	Stage 2 · wk 41	94	+1.4%
5	ASSTStrive, Inc. Class A	Stage 2 · wk 7	92	+0.1%
6	AMGAffiliated Managers Group, Inc.	Stage 2 · wk 21	91	+8.0%
7	WTWisdomTree, Inc.	Stage 2 · wk 39	91	−10.6%
8	VCTRVictory Capital Holdings, Inc.	Stage 2 · wk 39	91	+1.0%
…63	TPVGTriplePoint Venture Growth BDC Corp.	Stage 2 · wk 3	48	−12.6%

vs 52W High

-25.9%

$4.06 lo$5.80 hi

25.9% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 3

1w13w26w

Week 3, fresh breakout

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-10.8%

200 DMA: $4.82 · sloping down

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.96x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-12.6%

+2.7%

-7.9%

YTD

-25.0%

-8.2%

Scan Membership

Breakout Watch

Latest: 2025-01-16

9 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 3 · Vol 0.96x

2026-10-21S2

Wk 3 · Vol 1.42x

2026-10-20S2

Wk 2 · Vol 1.33x

2026-10-19S2

Wk 2 · Vol 0.96x

2026-10-16S2

Wk 2 · Vol 0.62x

2026-10-15S2

Wk 2 · Vol 0.58x

2026-10-14S2

Wk 2 · Vol 0.98x

2026-10-13S2

Wk 1 · Vol 1.28x

2026-10-12S2

Wk 1 · Vol 1.06x

2026-10-09S2

Wk 1 · Vol 0.48x

2026-10-08S2

Wk 1 · Vol 0.62x

2026-10-07S21→2

Wk 1 · Vol 0.81x

Moving averages & range

50 DMA

$4.84

200 DMA

$4.82

52W High

$5.80

52W Low

$4.06

5D Low

$4.25

Resistance levels (recent highs)

20d High

$4.90

60d High

$5.19

120d High

$5.40

250d High

$5.80

Next resistance

+14.0%

to 20d High

P/E (TTM)

4.3

Forward 5.2

Earnings Growth (YoY)

-19.8%

Revenue -5.2%

ROE

+11.5%

Profit margin +44.9%

Dividend Yield

30.73%

P/B 0.5

TriplePoint Venture Growth BDC: quick answers

What stage is TriplePoint Venture Growth BDC in?

As of Oct 22, 2026, TriplePoint Venture Growth BDC (TPVG) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 7, 2026 and is in week 3. What the four stages mean

Is TriplePoint Venture Growth BDC in an uptrend?

Yes. TriplePoint Venture Growth BDC is in a Stage 2 uptrend. It trades 10.8% below its 200-day average, which is falling.

How far is TriplePoint Venture Growth BDC from its 52-week high?

TriplePoint Venture Growth BDC closed at $4.30 on Oct 22, 2026, 25.9% below its 52-week high of $5.80. Its 52-week low is $4.06.

How has TriplePoint Venture Growth BDC performed over the past year?

As of Oct 22, 2026, TriplePoint Venture Growth BDC is down 8.2% over the past year and down 25.0% so far in 2026.

Which sector and industry is TriplePoint Venture Growth BDC in?

TriplePoint Venture Growth BDC is in the Asset Management industry, part of the Financials sector.

About this companyFinancials· Asset Management

TriplePoint Venture Growth BDC Corp. is a business development company specializing investments in venture capital-backed companies at the growth stage investments. It also provides debt financing to venture growth space companies which includes growth capital loans, secured and customized loans, equipment financings, revolving loans and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company's total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It targeted returns between 10% and 18%. It does not take board seat in the company.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.